- Home
- VOR vs ATRA Comparison
VOR vs ATRA Comparison
Compare VOR & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- ATRA
- Stock Information
- Founded
- VOR 2015
- ATRA 2012
- Country
- VOR United States
- ATRA United States
- Employees
- VOR N/A
- ATRA N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VOR Health Care
- ATRA Health Care
- Exchange
- VOR Nasdaq
- ATRA Nasdaq
- Market Cap
- VOR 202.4M
- ATRA 51.1M
- IPO Year
- VOR 2021
- ATRA 2014
- Fundamental
- Price
- VOR $2.42
- ATRA $8.83
- Analyst Decision
- VOR Buy
- ATRA Buy
- Analyst Count
- VOR 7
- ATRA 5
- Target Price
- VOR $3.77
- ATRA $17.75
- AVG Volume (30 Days)
- VOR 47.5M
- ATRA 34.7K
- Earning Date
- VOR 08-07-2025
- ATRA 08-11-2025
- Dividend Yield
- VOR N/A
- ATRA N/A
- EPS Growth
- VOR N/A
- ATRA N/A
- EPS
- VOR N/A
- ATRA N/A
- Revenue
- VOR N/A
- ATRA $199,732,000.00
- Revenue This Year
- VOR N/A
- ATRA N/A
- Revenue Next Year
- VOR N/A
- ATRA N/A
- P/E Ratio
- VOR N/A
- ATRA N/A
- Revenue Growth
- VOR N/A
- ATRA 475.53
- 52 Week Low
- VOR $0.13
- ATRA $5.01
- 52 Week High
- VOR $3.29
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- VOR 73.52
- ATRA 62.09
- Support Level
- VOR $2.25
- ATRA $9.11
- Resistance Level
- VOR $2.84
- ATRA $9.60
- Average True Range (ATR)
- VOR 0.54
- ATRA 0.44
- MACD
- VOR 0.10
- ATRA 0.09
- Stochastic Oscillator
- VOR 70.92
- ATRA 79.01
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).